Cobimetinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cobimetinib: From BRAF-Mutant Melanoma to Amyotrophic Lateral Sclerosis
One-Sentence Summary
Cobimetinib is an oral MEK1/2 inhibitor approved in the US and EU for BRAF V600E/K-mutant unresectable or metastatic melanoma in combination with vemurafenib. The TxGNN model predicts it may have therapeutic potential in Amyotrophic Lateral Sclerosis (ALS), supported by a plausible MEK/ERK pathway neuroprotection hypothesis. Currently, no clinical trials and no published literature document this repurposing direction, placing evidence at the lowest tier (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | BRAF V600E/K-mutant unresectable or metastatic melanoma (in combination with vemurafenib) |
| Predicted New Indication | Amyotrophic Lateral Sclerosis (ALS) |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 — Model prediction only, no clinical or preclinical studies retrieved |
| Saudi Arabia Market Status | Not Marketed (0 registered authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Cobimetinib is a selective, potent inhibitor of MEK1 and MEK2 kinases — core components of the RAS–RAF–MEK–ERK signaling cascade. This pathway governs cell proliferation, survival, and stress response. In BRAF-mutant melanoma, constitutive MEK/ERK hyperactivation drives tumor growth; cobimetinib suppresses this oncogenic signal. Its proven target engagement and favorable oral bioavailability make it pharmacologically attractive as a backbone for repurposing.
The mechanistic case for ALS centers on evidence that dysregulated MEK/ERK signaling contributes to neurodegeneration. TDP-43 proteinopathy — present in ~97% of ALS cases — can pathologically activate MAPK cascades, potentially amplifying neuroinflammation and accelerating motor neuron apoptosis. In this context, MEK inhibition may dampen microglial-mediated inflammatory responses and reduce downstream pro-apoptotic signaling in vulnerable motor neurons, offering a neuroprotective rationale.
However, a critical pharmacological barrier must be prospectively addressed: cobimetinib's blood-brain barrier (BBB) penetration is not well characterized for neurological indications. CNS drug exposure is a prerequisite for any centrally-acting therapy. Without confirmed BBB penetration and adequate target engagement in the spinal cord and motor cortex, the mechanistic hypothesis — however biologically coherent — cannot be assumed to translate into clinical efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered for Cobimetinib in amyotrophic lateral sclerosis.
Literature Evidence
Currently no related literature available for Cobimetinib in amyotrophic lateral sclerosis.
Saudi Arabia Market Information
Cobimetinib is not currently registered or marketed in Saudi Arabia. No product authorizations were found in the regulatory query (0 licenses, query date: 2026-03-29).
Cytotoxicity
Cobimetinib is classified as an antineoplastic agent (targeted therapy for melanoma); this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — selective MEK1/2 kinase inhibitor (small-molecule; not conventional cytotoxic) |
| Myelosuppression Risk | Low to moderate (anemia is reported; severe neutropenia or thrombocytopenia are uncommon compared to cytotoxic chemotherapy) |
| Emetogenicity Classification | Low |
| Monitoring Items | CBC with differential; liver function tests (ALT/AST — hepatotoxicity risk); creatine kinase (CK — myopathy/rhabdomyolysis risk); ophthalmic evaluation (serous retinopathy, retinal vein occlusion); cardiac monitoring (ejection fraction, QT interval); dermatologic assessment |
| Handling Protection | Standard targeted oral therapy handling applies; full cytotoxic closed-system transfer device (CSTD) protocols are typically not required, though institutional SOPs should be followed |
Safety Considerations
Please refer to the package insert for safety information. (Formal warning and contraindication data from Saudi Arabian and Taiwan regulatory databases were not retrieved in this Evidence Pack cycle. DDI query returned no results.)
Conclusion and Next Steps
Decision: Research Question
Rationale: TxGNN generates a high prediction score (99.73%) for cobimetinib in ALS via a biologically plausible MEK/ERK neuroprotection mechanism; however, evidence level is L5 — there are zero registered clinical trials and zero indexed publications supporting this specific repurposing hypothesis. Unconfirmed blood-brain barrier penetration represents an unresolved pharmacological prerequisite that must be established before any translational investment is justified.
To proceed, the following is needed:
- BBB penetration data: CNS pharmacokinetic studies (rodent or non-human primate) confirming adequate cobimetinib exposure in spinal cord and motor cortex at clinically tolerable doses
- Preclinical ALS proof-of-concept: Efficacy studies in established ALS models (e.g., SOD1-G93A transgenic mice, TDP-43 mutant models) measuring survival, motor function, and neuroinflammation endpoints
- Pathway validation in human tissue: Confirmation of MEK/ERK hyperactivation in post-mortem ALS spinal cord or iPSC-derived motor neurons from ALS patients
- Safety profile review for neurological populations: Formal assessment of cobimetinib's known toxicities (retinopathy, hepatotoxicity, cardiac effects) in the context of a chronic ALS treatment regimen
- Regulatory pathway consultation: Given non-marketed status in Saudi Arabia, early dialogue with SFDA on the repurposing regulatory framework would be required before any IND-equivalent application
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.